Novel soluble epoxide hydrolase inhibitor protects mitochondrial function following stress

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 6, 2012, Pages 811-823

  Batchu, Sri N ^a   Lee, Stephen B ^a   Samokhvalov, Victor ^a   Chaudhary, Ketul R ^a   El Sikhry, Haitham ^a   Weldon, Steven M ^b   Seubert, John M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Epoxyeicosatrienoic acid; Ischemia reperfusion; PmkATP channels and sEH inhibitors; Soluble epoxide hydrolase

Indexed keywords

14,15 EPOXYEICOSA 5 ENOIC ACID; 4 PENTENOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CASPASE 3; GLIBENCLAMIDE; HYDROLASE INHIBITOR; N (2 CHLORO 4 METHANESULFONYL BENZYL) 6 (2,2,2 TRIFLUORO ETHOXY)NICOTINAMIDE; NICOTINAMIDE; PROTEASOME; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANOXIA; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DNA BINDING; HEART LEFT VENTRICLE PRESSURE; IMMUNOBLOTTING; ISOLATED HEART; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REOXYGENATION; REPERFUSION INJURY;

ANIMALS; ANOXIA; ARACHIDONIC ACID; CASPASE 3; CELLS, CULTURED; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HEART; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED C57BL; MITOCHONDRIA, HEART; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY;

EID: 84870708283     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-082     Document Type: Article

References (40)

1. Anandan, S.K., Webb, H.K., Chen, D., Wang, Y.X., Aavula, B.R., Cases, S., et al. 2011. 1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-ylurea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. Bioorg. Med. Chem. Lett. 21(3): 983-988. doi:10.1016/j.bmcl.2010.12.042. PMID: 21211973.
2. Baczkó, I., Jones, L., McGuigan, C.F., Manning Fox, J.E., Gandhi, M., Giles, W.R., et al. 2005. Plasma membrane KATP channelmediated cardioprotection involves posthypoxic reductions in calcium overload and contractile dysfunction: mechanistic insights into cardioplegia. FASEB J. 19(8): 980-982. PMID:15774423.
3. Batchu, S.N., Law, E., Brocks, D.R., Falck, J.R., and Seubert, J.M. 2009. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J. Mol. Cell. Cardiol. 46(1): 67-74. doi:10.1016/j.yjmcc.2008.09.711. PMID: 18973759.
4. Batchu, S.N., Lee, S.B., Qadhi, R.S., Chaudhary, K.R., El-Sikhry, H., Kodela, R., et al. 2011. Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury. Br. J. Pharmacol. 162(4): 897-907. doi:10.1111/j.1476- 5381.2010.01093.x. PMID:21039415.
5. Bodiga, S., Zhang, R., Jacobs, D.E., Larsen, B.T., Tampo, A., Manthati, V.L., et al. 2009. Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels. J. Mol. Cell. Cardiol. 46(6): 978-988. doi:10.1016/j. yjmcc.2009.01.009. PMID:19336274.
6. Cadenas, S., Aragones, J., and Landazuri, M.O. 2010. Mitochondrial reprogramming through cardiac oxygen sensors in ischaemic heart disease. Cardiovasc. Res. 88(2): 219-228. doi:10.1093/cvr/ cvq256. PMID:20679415.
7. Capdevila, J.H., Wei, S., Kumar, A., Kobayashi, J., Snapper, J.R., Zeldin, D.C., et al. 1992. Resolution of dihydroxyeicosanoates and of dihydroxyeicosatrienoates by chiral phase chromatography. Anal. Biochem. 207(2): 236-240. doi:10.1016/0003-2697(92) 90006-S. PMID:1481976.
8. Chaudhary, K.R., Batchu, S.N., Das, D., Suresh, M.R., Falck, J.R., Graves, J.P., et al. 2009. Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function. Cardiovasc. Res. 83(2): 362-370. doi:10.1093/cvr/cvp134. PMID:19401302.
9. Chaudhary, K.R., Abukhashim, M., Hwang, S.H., Hammock, B.D., and Seubert, J.M. 2010. Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury. J. Cardiovasc. Pharmacol. 55(1): 67-73. doi:10.1097/FJC.0b013e3181c37d69. PMID:19834332.
10. Chiamvimonvat, N., Ho, C.M., Tsai, H.J., and Hammock, B.D. 2007. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J. Cardiovasc. Pharmacol. 50(3): 225-237. doi:10. 1097/FJC.0b013e3181506445. PMID:17878749.
11. Decker, M., Arand, M., and Cronin, A. 2009. Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch. Toxicol. 83(4): 297-318. doi:10.1007/s00204-009-0416-0. PMID:19340413.
12. DuTeaux, S.B., Newman, J.W., Morisseau, C., Fairbairn, E.A., Jelks, K., Hammock, B.D., and Miller, M.G. 2004. Epoxide hydrolases in the rat epididymis: possible roles in xenobiotic and endogenous fatty acid metabolism. Toxicol. Sci. 78(2): 187-195. doi:10.1093/ toxsci/kfh066. PMID:14737000.
13. El-Sikhry, H.E., Miller, G.G., Madiyalakan, M.R., and Seubert, J.M. 2011. Sonodynamic and photodynamic mechanisms of action of the novel hypocrellin sonosensitizer, SL017: mitochondrial cell death is attenuated by 11,12-epoxyeicosatrienoic acid. Invest. New Drugs, 29(6): 1328-1336. doi:10.1007/s10637-010-9495-2. PMID:20676746.
14. Eldrup, A.B., Soleymanzadeh, F., Farrow, N.A., Kukulka, A., and De Lombaert, S. 2010. Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase. Bioorg. Med. Chem. Lett. 20(2): 571-575. doi:10.1016/j.bmcl.2009.11.091. PMID:19969453.
15. Falck, J.R., Kodela, R., Manne, R., Atcha, K.R., Puli, N., Dubasi, N., et al. 2009. 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J. Med. Chem. 52(16): 5069-5075. doi:10.1021/jm900634w. PMID: 19653681.
16. Gross, G.J., Hsu, A., Falck, J.R., and Nithipatikom, K. 2007. Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J. Mol. Cell. Cardiol. 42(3): 687-691. doi:10.1016/j.yjmcc.2006.11.020. PMID:17217955.
17. Gross, G.J., Gauthier, K.M., Moore, J., Falck, J.R., Hammock, B.D., Campbell, W.B., and Nithipatikom, K. 2008. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am. J. Physiol. Heart Circ. Physiol. 294(6): H2838-H2844. doi:10.1152/ajpheart.00186.2008. PMID:18441205.
18. Halestrap, A.P., and Pasdois, P. 2009. The role of the mitochondrial permeability transition pore in heart disease. Biochim. Biophys. Acta, 1787(11): 1402-1415. doi:10.1016/j.bbabio.2008.12.017. PMID:19168026.
19. Katragadda, D., Batchu, S.N., Cho, W.J., Chaudhary, K.R., Falck, J.R., and Seubert, J.M. 2009. Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. J. Mol. Cell. Cardiol. 46(6): 867-875. doi:10.1016/j.yjmcc.2009.02.028. PMID:19285984.
20. Lu, T., Hoshi, T., Weintraub, N.L., Spector, A.A., and Lee, H.C. 2001. Activation of ATP-sensitive K(+) channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J. Physiol. 537(3): 811-827. doi:10.1113/jphysiol.2001.012896. PMID:11744757.
21. Luria, A., Weldon, S.M., Kabcenell, A.K., Ingraham, R.H., Matera, D., Jiang, H., et al. 2007. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J. Biol. Chem. 282(5): 2891-2898. doi:10.1074/jbc.M608057200. PMID:17135253.
22. Marinovic, J., Ljubkovic, M., Stadnicka, A., Bosnjak, Z.J., and Bienengraeber, M. 2008. Role of sarcolemmal ATP-sensitive potassium channel in oxidative stress-induced apoptosis: mitochondrial connection. Am. J. Physiol. Heart Circ. Physiol. 294(3): H1317-H1325. doi:10.1152/ajpheart.00840.2007. PMID: 18192220.
23. Monti, J., Fischer, J., Paskas, S., Heinig, M., Schulz, H., Gosele, C., et al. 2008. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat. Genet. 40(5): 529-537. doi:10.1038/ng.129. PMID:18443590.
24. Morisseau, C., and Hammock, B.D. 2005. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 45(1): 311-333. doi:10.1146/annurev.pharmtox.45.120403.095920. PMID:15822179.
25. Motoki, A., Merkel, M.J., Packwood, W.H., Cao, Z., Liu, L., Iliff, J., et al. 2008. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am. J. Physiol. Heart Circ. Physiol. 295(5): H2128-H2134. doi:10.1152/ajpheart.00428.2008. PMID:18835921.
26. Noma, A. 1983. ATP-regulated K+ channels in cardiac muscle. Nature, 305(5930): 147-148. doi:10.1038/305147a0. PMID: 6310409.
27. Roman, R.J. 2002. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82(1): 131-185. PMID:11773611.
28. 2+-dependent cell survival and death. Mol. Cell, 33(3): 377-388. doi:10.1016/j. molcel.2009.01.018. PMID:19217411.
29. Saito, T., Sato, T., Miki, T., Seino, S., and Nakaya, H. 2005. Role of ATP-sensitive K+ channels in electrophysiological alterations during myocardial ischemia: a study using Kir6.2-null mice. Am. J. Physiol. Heart Circ. Physiol. 288(1): H352-H357. doi:10. 1152/ajpheart.00695.2004. PMID:15598870.
30. Semenza, G.L. 2009. Regulation of oxygen homeostasis by hypoxiainducible factor 1. Physiology (Bethesda), 24(2): 97-106. doi:10. 1152/physiol.00045.2008. PMID:19364912.
31. + channels and p42/p44 MAPK pathway. Circ. Res. 95(5): 506-514. doi:10.1161/01.RES.0000139436.89654.c8. PMID: 15256482.
32. Seubert, J.M., Sinal, C.J., Graves, J., DeGraff, L.M., Bradbury, J.A., Lee, C.R., et al. 2006. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 99(4): 442-450. doi:10.1161/01.RES.0000237390.92932.37. PMID: 16857962.
33. Shen, H.C., Ding, F.X., Deng, Q., Xu, S., Chen, H.S., Tong, X., et al. 2009. Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors. Bioorg. Med. Chem. Lett. 19(18): 5314-5320. doi:10.1016/j.bmcl. 2009.07.138. PMID:19682899.
34. Spector, A.A., Fang, X., Snyder, G.D., and Weintraub, N.L. 2004. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical (03)00049-3. PMID:14636671.
35. Suzuki, M., Li, R.A., Miki, T., Uemura, H., Sakamoto, N., Ohmoto- Sekine, Y., et al. 2001. Functional roles of cardiac and vascular ATP-sensitive potassium channels clarified by Kir6.2-knockout mice. Circ. Res. 88(6): 570-577. PMID:11282890.
36. Suzuki, M., Sasaki, N., Miki, T., Sakamoto, N., Ohmoto-Sekine, Y., Tamagawa, M., et al. 2002. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J. Clin. Invest. 109(4): 509-516. PMID:11854323.
37. Taylor, S.J., Soleymanzadeh, F., Eldrup, A.B., Farrow, N.A., Muegge, I., Kukulka, A., et al. 2009. Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase. Bioorg. Med. Chem. Lett. 19(20): 5864-5868. doi:10.1016/j. bmcl.2009.08.074. PMID:19758802.
38. Yao, Z., Cavero, I., and Gross, G.J. 1993. Activation of cardiac KATP channels: an endogenous protective mechanism during repetitive ischemia. Am. J. Physiol. 264(2): H495-H504. PMID:8447462.
39. Zambrowicz, B.P., Friedrich, G.A., Buxton, E.C., Lilleberg, S.L., Person, C., and Sands, A.T. 1998. Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature, 392(6676): 608-611. doi:10.1038/33423. PMID:9560157.
40. Zhang, W., Koerner, I.P., Noppens, R., Grafe, M., Tsai, H.J., Morisseau, C., et al. 2007. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 27(12): 1931-1940. doi:10.1038/sj.jcbfm.9600494. PMID:17440491.